Antifungal product, use and formulation thereof

Abstract

An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C max at different times.

What is claimed is:  
     
         1 . An antifungal product comprising: a first antifungal dosage form, a second antifungal dosage form, and a third antifungal dosage form, each of said first, second and third antifungal dosage forms comprising an antifungal and a pharmaceutically acceptable carrier, said three dosage forms having different release profiles, said antifungal product reaching a C max  in less than about twelve hours.  
     
     
         2 . The product of  claim 1  wherein the first dosage form is an immediate release dosage form.  
     
     
         3 . The product of  claim 2  wherein the C max  for the product is reached no earlier than four hours after administration.  
     
     
         4 . The product of  claim 2  wherein the immediate release dosage form contains at least 20% and no more than 50% of the total dosage of antifungal.  
     
     
         5 . The product of  claim 4  wherein the product is an oral dosage form.  
     
     
         6 . The product of  claim 5  wherein the antifungal released from the second dosage in the form reaches a C max  in the serum after C max  is reached in the serum for antifungal released from the first dosage form.  
     
     
         7 . The product of  claim 6  wherein the antifungal released from the third dosage form reaches a C max  in the serum after the antifungal released from the second dosage form reaches a C max  in the serum.  
     
     
         8 . The antifungal product of  claim 1  wherein said antifungal product includes a total dosage of antifungal that is effective for a twenty four hour period.  
     
     
         9 . The product of  claim 1  and further comprising a fourth antifungal dosage form comprising an antifungal and a pharmaceutically acceptable carrier, wherein antifungal released from the fourth dosage form reaches a C max  in the serum after C max  is achieved in the serum for antifungal released from each of the first, second and third dosage forms.  
     
     
         10 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of  claim 1 .    
     
     
         11 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of  claim 2 .    
     
     
         12 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of  claim 3 .    
     
     
         13 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of  claim 4 .    
     
     
         14 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of  claim 5 .    
     
     
         15 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of  claim 6 .    
     
     
         16 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of  claim 7 .    
     
     
         17 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of  claim 8 .    
     
     
         18 . A process for treating a fungal infection in a host comprising: 
 administering to a host the antifungal product of claim  9 .